US 12,264,337 B2
Differentiation of pancreatic endocrine cells
George Harb, Boston, MA (US); and Chunhi Xie, Belmont, MA (US)
Assigned to Vertex Pharmaceuticals Incorporated, Boston, MA (US)
Filed by Vertex Pharmaceuticals Incorporated, Boston, MA (US)
Filed on Sep. 4, 2024, as Appl. No. 18/824,588.
Application 18/824,588 is a continuation of application No. 17/988,257, filed on Nov. 16, 2022.
Application 17/988,257 is a continuation of application No. 17/390,839, filed on Jul. 30, 2021, granted, now 12,049,645, issued on Jul. 30, 2024.
Claims priority of provisional application 63/059,433, filed on Jul. 31, 2020.
Prior Publication US 2024/0425818 A1, Dec. 26, 2024
This patent is subject to a terminal disclaimer.
Int. Cl. C12N 5/071 (2010.01); A61K 35/39 (2015.01)
CPC C12N 5/0676 (2013.01) [A61K 35/39 (2013.01); C12N 2501/11 (2013.01); C12N 2501/15 (2013.01); C12N 2501/155 (2013.01); C12N 2501/415 (2013.01)] 30 Claims
 
1. A method of treating a subject having diabetes, comprising administering to the subject a composition comprising a plurality of in vitro differentiated cells in a plurality of cell clusters; wherein the cell clusters comprise a plurality of cells that express insulin; wherein at least 80% of the cells in the composition are ISL1-positive cells; and wherein the cell clusters in the composition are between 75 and 250 microns in diameter.